Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program
Tóm tắt
Từ khóa
Tài liệu tham khảo
Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41: 143-149.
Listernick R, Darling C, Greenwald M, Strauss L, Charrow J. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestation and natural history. J Pediatr. 1995;127: 718-722.
Rosser t, Packer RJ. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol. 2002;17: 630-637.
Garvey M, Packer RJ. An integrated approach to the treatment of chiasmatic-hypothalamic gliomas. J Neurooncol. 1996;28: 167-183.
Laithier V, Grill J, Le Deley M, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy—results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21: 4572-4578.
Gnekow AK, Kortmann RD, Pietsch T, Emser A. Low grade chiasmatic-hypothalamic glioma—carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy—report from the Multicenter treatment Study for Children and Adolescents with a Low Grade Glioma—HIT-LGG 1996—of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr. 2004;216: 331-342.
King A, Listernick R, Charrow J, Piersall L, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet. 2003;122A: 95-99.
Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20: 4209-4216.
Kortmann RD, Timmermann B, Taylor RE, et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: treatment-related late toxicity. Strahlenther Onkol. 2003;179: 585-597.
De Bella K, Szudek J, Friedman JM. Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105; 608-614.
Dodge HJ, Love J, Craig W, et al. Gliomas of the optic nerves. AMA Arch Neurol Psychiatry. 1958;79: 607-621.
Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol. 2001;131: 442-445.
Janss AJ, Grundy R, Cnaan A, et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer. 1995;75: 1051-1059.
Sutton LN, Molloy PT, Sernyak H, et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg. 1995;83: 583-589.
Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology. 2004;111: 568-577.
Gayre GS, Scott IU, Feuer W, Saunders TG, Siatkowski RM. Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuroophthalmol. 2001;21: 1-7.